Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06742892
What this trial is testing

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

Who this might be right for
Carcinoma, Hepatocellular
Shanghai Henlius Biotech 90
Testing effectiveness (Phase 2)Ended earlyNCT04812535
What this trial is testing

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Who this might be right for
SCC - Squamous Cell Carcinoma of Skin
InflaRx GmbH 30
Large-scale testing (Phase 3)Study completedNCT03088540
What this trial is testing

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma，Non-Small-Cell LungLung Carcinomas, Non-Small-CellNon-small-cell Lung Carcinoma+1 more
Regeneron Pharmaceuticals 712
Testing effectiveness (Phase 2)UnknownNCT04202809
What this trial is testing

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.

Who this might be right for
NSCLC, Stage III
University Hospital, Essen 90
Not applicableStudy completedNCT03832348
What this trial is testing

Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment

Who this might be right for
Non Small Cell Lung Cancer
Centre Henri Becquerel 40
Testing effectiveness (Phase 2)Study completedNCT03955198
What this trial is testing

A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation

Who this might be right for
NSCLC
Institut Claudius Regaud 4
Large-scale testing (Phase 3)Study completedNCT03615326
What this trial is testing

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC 738
Testing effectiveness (Phase 2)WithdrawnNCT03150836
What this trial is testing

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
Terence Friedlander, MD
Not applicableUnknownNCT03029858
What this trial is testing

PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients

Who this might be right for
Small Cell Lung Cancer, Polygonal Type
Guangdong Association of Clinical Trials 155
Not applicableEnded earlyNCT03412058
What this trial is testing

Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

Who this might be right for
MelanomaNon Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma
UNICANCER 152
Testing effectiveness (Phase 2)Looking for participantsNCT06001658
What this trial is testing

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Who this might be right for
Billiary Track Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27
Testing effectiveness (Phase 2)Looking for participantsNCT06445972
What this trial is testing

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Who this might be right for
Gastroesophageal JunctionGastroesophageal AdenocarcinomaEsophageal Neoplasms+1 more
Merck Sharp & Dohme LLC 210
Large-scale testing (Phase 3)Study completedNCT03829319
What this trial is testing

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Who this might be right for
Nonsquamous Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 761
Large-scale testing (Phase 3)Active Not RecruitingNCT04660344
What this trial is testing

Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

Who this might be right for
Muscle-invasive Bladder Cancer
Hoffmann-La Roche 761
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07142863
What this trial is testing

Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients

Who this might be right for
OsteosarcomaNeoadjuvant TherapyNeoadjuvant Chemotherapy+2 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 23
Large-scale testing (Phase 3)Active Not RecruitingNCT03706690
What this trial is testing

Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 407
Testing effectiveness (Phase 2)Study completedNCT02087423
What this trial is testing

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 446
Early research (Phase 1)Study completedNCT02503774
What this trial is testing

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Who this might be right for
Solid Tumors
MedImmune LLC 192
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05280626
What this trial is testing

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Who this might be right for
Diffuse Large B-Cell Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 100
Not applicableStudy completedNCT03732560
What this trial is testing

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Who this might be right for
Melanoma
Bristol-Myers Squibb 600
Next Page